Life Extension Blood Test Super Sale

Life Extension Update

July 22, 2004
In this issue

Life Extension Update Exclusive:

Vitamin K helps protect cirrhosis patients from developing liver cancer

Protocol:

Liver cirrhosis

Featured Products:

Super K with vitamin K2

Hepatopro capsules

Life Extension Update Exclusive

Vitamin K helps protect cirrhosis patients from developing liver cancer
A report appearing in the July 21 2004 issue of the Journal of the American Medical Association revealed the findings of researchers from Osaka City University in Osaka, Japan, that supplementation with vitamin K reduced the risk of hepatocellular carcinoma in women with viral cirrhosis of the liver to 20 percent of that experience by those who were not treated with the vitamin. Cirrhosis of the liver can cause malignant changes in the organ, leading to hepatocellular carcinoma, the most common type of liver cancer.

The study included women with cirrhosis caused by the hepatitis B or C virus who were enrolled in another study that measured the effect of vitamin K2 (a natural form of the vitamin) on bone loss. In the current study, twenty-one women who were confirmed by angiography or biopsy not to have pre-existing hepatocellular carcinoma received 45 milligrams vitamin K2 per day, while nineteen served as controls. During eight years of follow up, hepatocellular carcinoma was detected in nine (8.8 percent) of the control participants and in two (1.6 percent) of those who received vitamin K. Of several possible risk factors analyzed, low serum albumin levels emerged as the most predictive of the development of hepatocellular carcinoma.

In their commentary, the authors note vitamin K’s ability to inhibit tumor growth in culture. A possible mechanism for vitamin K could involve be the induction of proteins with growth-inhibitory properties such as prothrombin. They conclude that vitamin K treatment may delay the onset of hepatocarcinogenesis and note that the safety, low cost and ease of use of vitamin K2 led to good patient compliance.

Protocol

Liver Cirrhosis
Until recently, the most common cause of cirrhosis of the liver in the United States was attributed to alcohol abuse. Hepatitis C is now the number one cause of liver cirrhosis (26%), followed closely by alcohol abuse at 21% (NIDDK 2000). A cofactor such as the hepatitis C virus can increase the risk of cirrhosis in those who also consume alcohol in excess (NIDA 2002).

In the United States, a type of cancer known as hepatocellular carcinoma is observed in 10-20% of patients who have cirrhosis (Wolf 2001). As with other cancers, early detection and number and size of tumors influence survival. Treatment for HCC ranges from surgical removal of the HCC if the patient has good liver function to transplantation (NIDDK 2000; Columbo 2001; Wolf 2001). If the patient cannot have surgery (because of advanced age, other health conditions, poor liver function, large tumors, or tumors in strategic locations), possible treatment includes ultrasound-guided injection of solutions that cause necrosis of tumor cells in the cancerous area; using a catheter to eliminate blood supply to the tumor; injecting antitumor agents directly into the tumor; systemic chemotherapy; and radiation (Columbo 2001).

Because the liver can often continue to perform essential functions in spite of serious damage, it is important to eat foods and take proper nutrients to retain its regeneration and detoxification abilities.

Phosphatidylcholine (PC) is one of the most important substances for liver protection and health and is a primary constituent of the cell membrane. As such, PC is necessary for integrity of liver cells. In studies in rats, PC has prolonged the survival of rat liver cells in culture by stabilizing the cell membrane (Miyazak et al. 1991). Liver cells that have been damaged by alcohol or cirrhosis are unable to meet the ongoing demands of the liver for phospholipid synthesis. Adding phospholipids such as PC via oral intake played an important role in regeneration of damaged liver cells (Horejsova et al. 1994). In an early study, Neuberger (1983) stated: "It has been shown that orally administered polyunsaturated PC can be incorporated into the liver cell membrane."

Other studies have shown the antifibrotic effect of PC. Not only does PC inhibit the development of hepatic fibrosis, it actually accelerates the regression of existing fibrosis (Ma et al. 1996). Part of this effect is probably due to PC promoting the breakdown of collagen (Lieber 1999), but it may also be due to an inhibitory effect on the stellate cell (Poniachik et al. 1999). In experimental studies, PC was also found to protect against alcoholic cirrhosis in baboons and against carbon tetrachloride-induced cirrhosis in rats (Aleynik et al. 1997). In another study (Navder et al. 1997), PC was shown to prevent earlier changes induced in the alcoholic liver before cirrhosis even develops.

http://www.lef.org/protocols/prtcl-068.shtml

Featured Products

Super K with K2

Arterial calcification is characterized as a buildup of calcium in the arterial walls. It is a process that can begin as early as the second decade of life and continue throughout adulthood. Although calcium is an essential nutrient in maintaining human bone integrity, the trick is to keep it out of the arteries. Studies have revealed that adequate levels of vitamin K may help in keeping calcium in bones and out of arterial walls.

Life Extension’s Super K provides 9 mg of K1 (phylloquinone) along with 1 mg of K2 (menaquinone) in each oil-based softgel.

http://www.lef.org/newshop/items/item00604.html

HepatoPro capsules

HepatoPro contains polyenylphosphatidylcholine (PPC), a soy extract that is listed in the Physician’s Desk Reference of the United States. PPC helps maintain the fluidity and integrity of cell membranes, which is vital to good health. PPC also helps promote the breakdown of excess collagen in the liver, which can interfere with normal detoxification processes. An accumulating body of research suggests that PPC’s health benefits may extend from the liver to the stomach, pancreas, and cardiovascular system. There are no known contraindications, side effects or interactions with other drugs.

http://www.lef.org/newshop/items/item00656.html

If you have questions or comments concerning this issue or past issues of Life Extension Update, send them to ddye@lifeextension.com or call 954 766 8433 extension 7716.

For longer life,

Dayna Dye
Editor, Life Extension Update
ddye@lifeextension.com
LifeExtension.com
1100 West Commercial Boulevard
Fort Lauderdale FL 33309
954 766 8433 extension 7716

Sign up for Life Extension Update at http://mycart.lef.org/subscribe.asp

Help spread the good news about living longer and healthier. Forward this email to a friend!

View previous issues of Life Extension Update in the Newsletter Archive.